Skip to main content
https://pbs.twimg.com/media/FpQfZL7WYAEJAnm.jpg
Deucravacitinib - Effective in Systemic Lupus Erythematosus A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE. https://t.co/YS8n02BEsk https://t.co/4sBd88AhtK
Dr. John Cush
18-02-2023
×